Chrysalis BioTechnology, Inc. is a biopharmaceutical company developing new therapeutics to accelerate the healing of hard and soft tissue. The Company's lead product, Chrysalin®, is currently in Phase III human clinical for bone fracture healing, and Phase II trials for chronic diabetic ulcers.
